1 |
Triagem in silico e avalia??o in vitro de compostos antifalcizantesPaz, Odailson Santos 25 May 2017 (has links)
Submitted by Ricardo Cedraz Duque Moliterno (ricardo.moliterno@uefs.br) on 2017-08-08T21:31:24Z
No. of bitstreams: 1
TESE_Odailson Paz - com ficha.pdf: 4071411 bytes, checksum: 033f0c18eb721e7010e1ddd7ec27e10c (MD5) / Made available in DSpace on 2017-08-08T21:31:24Z (GMT). No. of bitstreams: 1
TESE_Odailson Paz - com ficha.pdf: 4071411 bytes, checksum: 033f0c18eb721e7010e1ddd7ec27e10c (MD5)
Previous issue date: 2017-05-25 / Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior - CAPES / Adenosine receptors are considered as potential targets for the development of drugs against different pathologies because they are involved in several physiological pathways. Due to the role of adenosine receptors of subtype 2B (RA2B) in the process of sickling cell, antagonists capable of blocking RA2B may be lead compounds for the development of new therapeutic alternatives to treatment of patients with sickle cell anemia. Then, the objective of this work was to identify anti-sickle cell agents capable of blocking RA2B activity. To achieve this goal, was built a pharmacophore model (model 04) capable of differentiating true ligands false-positive (area under the ROC curve = 0.94) and to classify RA2B antagonists, not used in the calibration of the model, regarding their Biological activities pKi = 7.5-9.3 (high potency), 5.5-7.4 (intermediate potency) and 5.4-4.0 (low potency). This pharmacophore model allowed the selection of 33 lead-like compounds from the ZINC database, between them12 compounds presented anti-sickle cell activity. In vitro cell assay with an agonist (NECA) and a RA2B antagonist (MRS1754), suggest that the anti-sickle cell activity is related to modulation of RA2B. Compounds Z1139491704 (pEC50= 7,77?0,17), Z168278894 (pEC50= 7,64?0,09) e Z847449186 (pEC50= 7,66?0,21) have anti-sickling activity Higher than MRS1754 (pEC50= 7,63?0,12) and do not present cytotoxic activity at micromolar range. In sum, it can be concluded that the in silico strategy used succeeded in identifying compounds with probable action antagonists of RA2B that can be considered as prototypes for the development of drugs useful in the treatment of patients with sickle cell anemia. / Os receptores de adenosina s?o considerados como alvos potenciais para o desenvolvimento de f?rmacos contra diferentes patologias por estarem envolvidos em diversas vias fisiol?gicas. Devido ao papel dos receptores de adenosina do subtipo 2B (RA2B) no processo de falciza??o de hem?cias, antagonistas capazes de bloquear RA2B podem ser compostos prot?tipos para o desenvolvimento de novas alternativas terap?uticas para o tratamento de pacientes com anemia falciforme.Diante desse cen?rio, o objetivo desse trabalho foi identificar agentes antifalcizantes capazes de antagonizar a atividade do RA2B. Para alcan?ar esse objetivo foi constru?do um modelo farmacof?rico (modelo 04 - 3 caracter?sticas aceptor e 1 doador de liga??o de hidrog?nio e 3 centros hidrof?bicos) que ? capaz de diferenciar ligantes verdadeiros de falso-positivos (?rea sob a curva ROC= 0,94)e classificar antagonistas de RA2B,n?o utilizados na calibra??o do modelo, quanto as suas atividades biol?gicas(pKi= 7,5-9,3 (alta pot?ncia), 5,5-7,4 (pot?ncia intermedi?ria) e 5,4-4,0 (baixa pot?ncia)). Esse modelo farmacof?rico permitiu a sele??o de 33 compostos lead like do banco de dados ZINC database para avalia??o biol?gica, dos quais 12 apresentaram atividade antifalcizante.Testes in vitro com um agonista (NECA) e um antagonista de RA2B (MRS1754), sugerem que a atividade antifalcizante est? relacionada a modula??o de RA2B.Os compostosZ1139491704(pEC50= 7,77?0,17),Z168278894 (pEC50= 7,64?0,09) e Z847449186 (pEC50= 7,66?0,21)possuem atividade antifalcizante superior ao MRS1754 (pEC50=7,63?0,12)e n?o apresentam atividade citot?xica em concentra??es micromolares. Dessa forma, pode-se concluir que a estrat?gia in silico utilizada logrou sucesso em identificar compostos com prov?vel a??o antagonistas de RA2B que podem ser considerados como prot?tipos para o desenvolvimento de f?rmacos ?teis no tratamento de pacientes com anemia falciforme.
|
Page generated in 0.2407 seconds